This conference call will therefore be in the format of a questions-and-answer session where will address queries investors and analysts have regarding our Company's results. Our expectation is that the year in review document will serve as a useful resource for those of you interested in acquiring a deeper understanding of our progress and then this new approach will provide more room for discussion.
Now I'll turn the call over to the operator to open the telephone lines for Q&A.
Operator
Thank you. (Operator Instructions) Thank you. Our first question is from the line of Andrew D'Silva with B. Riley FBR. Please proceed with your question.
Andrew D'Silva -- B. Riley FBR -- Analyst
Good afternoon. Thanks for taking my questions. I read through your year in review. I'd have to admit, I did have another company reporting the same time, so I'm going to review it one more time, but I did see that you mentioned that four MAAs and two BLAs were filed last year. I was curious, out of those six, how many of those were Cryoport partners?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Andrew, Mark will answer that question.
Mark W. Sawicki -- Chief Commercial Officer
Of the six that were filed, five of them were related to business that we're supporting.
Andrew D'Silva -- B. Riley FBR -- Analyst
Okay, great. And have you seen -- this was probably the biggest quarter-over-quarter from a number standpoint, increase in total clinical trials that you are -- you've been in, at least since -- recent history. Could you maybe describe what you view as the catalyst that took place during the quarter? Are you seeing perhaps clients that were previously utilizing other forms of cryogenic shipping and storage shift over to what you're looking at or what you're offering? And then this is more related to internally within existing customer, for example, with Novartis, who has a numerous trials ongoing and newer subsidiaries as well.
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Well, that certainly has a lot of components to it, Andrew, it's a long question. So, because of its complexity, I'm going to turn it over to Mark Sawicki.
Mark W. Sawicki -- Chief Commercial Officer
Andrew, yeah, so couple of things to take into account when you're looking at our trial number for this particular quarter. First and foremost is, yes, we've seen additional growth in our network of trials that are being supported and this comes from two different sources, one is, us playing third-parties and that may have been supported by an alternative option. And the second is, expansion of clinical trial portfolios within our existing trial base or client base. But the second component is, we've started also reporting Europe as an additional number in the number of trials reported out of Europe because it has hit a critical mass and that number for the quarter was, well, a net add of about 40 trials for the overall number. And so it's a combination of both.
Andrew D'Silva -- B. Riley FBR -- Analyst
Okay. I see. And so in the years past or quarters past, you did not -- it was just the US trials that you were including that number?
Mark W. Sawicki -- Chief Commercial Officer
Correct. But we hit a critical mass in Europe. So we felt it was appropriate to start reporting on that as well.
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Andrew, actually you'll see in the year in review, there's a different color for the European trials on the chart on Page 5.
Andrew D'Silva -- B. Riley FBR -- Analyst
I see, I saw that, I just haven't fully digested everything just yet, but I will review one more time, absolutely. And this is just obviously a current event with Scott Gottlieb resigning effective, I guess next month. I was just curious how you see that and if you view it potentially impacting, anything that you're doing or benefiting it. And I know, last quarter you were out pursuing the ISO 276, just curious how that all kind of tied together?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
So -- I didn't get the full question. Did you get it?
Mark W. Sawicki -- Chief Commercial Officer
Yes. So, the Gottlieb announcement from our perspective, it's far too early to really honestly get any understanding of whether or not it'll have an impact on the regenerative medicine space. I think everybody is seeing the quotes that he put out before. He resigned back in January where he anticipated up to 20 filings a year within 2021-2022 timeframe. Our expectation and hope is that, obviously that's absolutely correct. But it's far too early to understand whether or not his resignation will have any impact on that overall strategy.
Andrew D'Silva -- B. Riley FBR -- Analyst
Okay, perfect. And last two-part question, actually. Just related to the off-the-shelf market and your potential M&A strategy, so this is a question I get from investors a lot just related to how you play in the off-the-shelf space? And when you're thinking about M&A, is it related to repository activity or are you thinking about things from a different aspect?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Andrew, we have talked about this a number of times in the past and we're very measured on what we do, what we entertain in the M&A area and we'll look at things in the space that we're in right now in terms of increasing our depth or we'll look at adjacencies to expand our footprint. And what I mean by where we are today, we'll look at software companies, we'll look at components of manufacturing that could provide strategic advantage. We'll also look at adjacencies and we talked about some of those in the past, like storage and like, again, software and other services that we think fit with our Company. So, we definitely are looking at them, but we have yet to pull the trigger.
Andrew D'Silva -- B. Riley FBR -- Analyst
Great. And on the off-the-shelf side of business?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
You're talking about the (inaudible)?
Andrew D'Silva -- B. Riley FBR -- Analyst
Yes.
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
(inaudible) Mark, because that is a developing part of our business, and I'll turn it to Mark, it's a great part of our business and we are looking forward to that development. So, Mark...
Mark W. Sawicki -- Chief Commercial Officer
Yes, our allogeneic portfolio is very strong. We're extremely active with most of the big players in the space that are dealing with allogeneic late phase clinical pipeline and we're well situated to support any eventual launch activity on any of those therapies on a global basis.
Andrew D'Silva -- B. Riley FBR -- Analyst
Okay, perfect. Great. Well, that's all I have. Thank you very much and look forward to talking guys offline.
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Thank you, Andrew.
Mark W. Sawicki -- Chief Commercial Officer
Thanks.
Operator
Thank you. (Operator Instructions) Our next question is from the line of Richard Baldry with Roth Capital. Please proceed with your question.
Richard Baldry -- Roth Capital -- Analyst
Thanks. When I look at the past couple years of data either including commercial or not, it appears there is a stronger seasonality starting the year in Q1 periods than ending the year in Q4s. It's a small amount of data. Do you think that's a real seasonal pattern or is it too smaller sample, there's reasons to not necessarily believe that when we think about seasonality in revenue for 2019 versus maybe 2018's and 2017's cadence?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Rich, we think that's, it's too early to call that. We do deal with lab products and we can be affected by releases by -- we can be affected by weather, we can be affected by a number of things. But it's too early for us to call seasonality with any kind of clarity.
Richard Baldry -- Roth Capital -- Analyst
Okay. And we saw an approval in Japan of its first regenerative therapy through its systems. Do you feel like there is a need to put another dedicated facility in the APAC area, similar what you've done recently in Europe or is it too early for that, how do we think about your infrastructure expansion plans in 2019 and beyond?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Rich, there is no question that APAC is developing and we certainly have our own and we support a number of trials in APAC, today. So we are evaluating that and there will be more to come on it, but I have no further comment on that at this point.
Richard Baldry -- Roth Capital -- Analyst
All right. Thank you.
Operator
Thank you. Our next question is from the line of Larry Smith with Smith On Stocks. Please proceed with your question.
Larry Smith -- Smith On Stocks -- Analyst
Thank you. I do a calculation to try to relate your revenues to those of Kymriah and Yescarta. So what I simply do is take the revenues that you report from commercial products and divide by revenues reported by Gilead and Novartis. So if I do that, I get that your recorded -- your revenues were 0.61% of Yescarta and Kymriah sales in the first quarter, 0.53% in the second quarter, 0.56% in the third quarter and 0.74% in the fourth quarter. If my numbers are correct, it's a very significant increase in the percentage that you receive of CAR-T revenues and I'm curious as to whether this is -- that can be explained or whether it's just kind of random, were those numbers going along?
Mark W. Sawicki -- Chief Commercial Officer
Yes, I'd be happy to answer that. So one of the things that we're always working to do is diversify our revenue streams within our given -- existing relationships and as these therapies launch on a more global basis, there's a lot of other ancillary or other support activities from our program management standpoint, consulting, validation work and other things that tie into supporting the launch activities and the ongoing ramps of these particular projects. So it's by design, you know, our goal always is to try to obviously increase the depth and the reach of what we're doing for these accounts. And so that's evidence of that effort.
Larry Smith -- Smith On Stocks -- Analyst
If my numbers are correct that there is a big increase in the percentage in 4Q over 3Q, should I then use -- should I use that to project revenues forward into the 2019 quarters? I used 0.74% of revenues as opposed to something like 0.56% of Kymriah and Yescarta revenues?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
We'll direct that question to Robert Stefanovich, Larry.
Robert S. Stefanovich -- Chief Financial Officer, Treasurer and Corporate Secretary
Yes, in terms of other revenues, as Mark already mentioned in his response, we are broadening the revenue with both Novartis and with Kite, as well as broadening the revenue stream within the commercial launch support. I mean, when we look at tying it directly to revenue, you can work with that percentage. I'd probably use an average of the last two, three months going forward. But then as you go into the latter part of next year, you should see that percentage increase further just based on the additional activities that we provide related to consulting services, engineering services and other services that we provide to both Kite and Novartis.
Larry Smith -- Smith On Stocks -- Analyst
Okay. Let me ask you a hypothetical question. As you're moving from CAR-T to (inaudible) gene therapy products where the number of patients may be somewhat less, my calculation in my asking is that you had about three -- that Kymriah and Yescarta are selling in a net price of about $325,000 per patient. What I'm curious is, if you were to supply logistics to a gene therapy company which doesn't have the same patient population as of CAR-Ts, where you might only be dealing with much less number of patients, but where the net price might be a $1 million or $2 million or $3 million, would the amount of revenues that you derive from such a gene therapy company be proportional to revenues or proportional to number of patients treated?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
It's more -- so, revenue or patients, so, it'd be more related to patients and dosages, Larry. It depends on the indication and it depends on the protocol for the therapy. So, both of those things would relate to the patient as opposed to the revenue.
Larry Smith -- Smith On Stocks -- Analyst
Okay. And if I could ask one final question. In the case of allogeneic therapies, CAR-T therapies are -- which are way down the line, of course, it seems to me that you will probably need an on-site cold facility, if the allogeneic cells kept on site. And if so, is that a meaningful new part of your business or how would you put that in perspective if my assumption is correct?
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Well, Larry, your assumption is partially correct. There is a variety of models developing right now for both autologous and allogeneic, and there will be shipments of allogeneic in bulk as well as being sold (ph) on-site. And so, we are in touch with our clients and we are in touch with the market and we are developing various models. As I always say, in this business, you have to be sort of in the athletic stance, be ready to move in any direction because the clarity is not yet there. I mean this is an evolving market and we're an evolving company serving that evolving market. So it's not clear exactly how the impact of allogeneic but we are ready to serve either market. They both -- we think the allogeneic market will be very, very good for us and we do have several models that we are ready to deploy when required.
Larry Smith -- Smith On Stocks -- Analyst
Okay. Thank you.
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Do you have anything to add, Mark?
Mark W. Sawicki -- Chief Commercial Officer
Yes, let me just add one other element on that. One of the key that we do is, we work very, very closely with our client base, almost on a strategic basis to help define what that product life cycle looks like. And so we would -- we sit down with these folks as they go through that commercial readiness process and we play a fairly large role in that strategy. And so regardless, like Jerry said of whatever -- overall strategy, they have from a market access standpoint, we have the ability to have a significant role in helping design that.
Larry Smith -- Smith On Stocks -- Analyst
Okay. Great quarter. Terrific execution. Congratulations, and thanks for taking my questions.
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Thank you, Larry.
Mark W. Sawicki -- Chief Commercial Officer
Thanks.
Operator
Thank you. There are no further questions at this time. So I'd like to turn the floor back over to management for closing comments.
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Well, thank you all for joining us today. It was a very simulating brief discussion. And I hope you like our new format and that it helps you see the exciting future we see ahead of us at Cryoport. So until the next call, we bid you farewell.
Operator
Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
Duration: 20 minutes
Todd Fromer -- Managing Partner
Jerrell W. Shelton -- Chairman, President and Chief Executive Officer
Andrew D'Silva -- B. Riley FBR -- Analyst
Mark W. Sawicki -- Chief Commercial Officer
Richard Baldry -- Roth Capital -- Analyst
Larry Smith -- Smith On Stocks -- Analyst
Robert S. Stefanovich -- Chief Financial Officer, Treasurer and Corporate Secretary
More CYRX analysis
Transcript powered by AlphaStreet
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.
More From The Motley Fool
Motley Fool Transcribers has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
